11.88
price down icon1.00%   -0.12
after-market アフターアワーズ: 11.88
loading
前日終値:
$12.00
開ける:
$11.99
24時間の取引高:
217.32K
Relative Volume:
0.97
時価総額:
$346.01M
収益:
$69.21M
当期純損益:
$-61.98M
株価収益率:
-4.5786
EPS:
-2.5947
ネットキャッシュフロー:
$-9.61M
1週間 パフォーマンス:
-2.62%
1か月 パフォーマンス:
-15.62%
6か月 パフォーマンス:
-2.38%
1年 パフォーマンス:
+53.29%
1日の値動き範囲:
Value
$11.64
$12.00
1週間の範囲:
Value
$11.64
$12.47
52週間の値動き範囲:
Value
$7.05
$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
名前
Enanta Pharmaceuticals Inc
Name
セクター
Healthcare (1067)
Name
電話
617 607 0800
Name
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
職員
120
Name
Twitter
@EnantaPharma
Name
次回の収益日
2026-11-16
Name
最新のSEC提出書
Name
ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ENTA icon
ENTA
Enanta Pharmaceuticals Inc
11.88 346.01M 69.21M -61.98M -9.61M -2.5947
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-26 開始されました Rodman & Renshaw Buy
2025-11-14 開始されました JP Morgan Overweight
2025-10-01 アップグレード Jefferies Hold → Buy
2025-07-28 再開されました H.C. Wainwright Buy
2023-08-09 ダウングレード JP Morgan Neutral → Underweight
2023-08-08 ダウングレード Jefferies Buy → Hold
2022-12-09 開始されました H.C. Wainwright Buy
2022-07-06 アップグレード Evercore ISI In-line → Outperform
2022-06-01 アップグレード Evercore ISI Underperform → In-line
2021-10-07 開始されました Jefferies Buy
2021-09-09 開始されました SVB Leerink Mkt Perform
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2020-11-24 開始されました Evercore ISI Underperform
2020-08-28 再開されました ROTH Capital Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-27 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 アップグレード Robert W. Baird Neutral → Outperform
2019-11-22 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 ダウングレード JP Morgan Neutral → Underweight
2019-05-24 開始されました Wolfe Research Outperform
2019-04-23 アップグレード Berenberg Hold → Buy
2018-12-13 開始されました Berenberg Hold
2018-06-06 開始されました ROTH Capital Buy
2018-02-08 ダウングレード JP Morgan Overweight → Neutral
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-11-21 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-07-11 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました Barclays Underweight
2015-10-23 ダウングレード Barclays Equal Weight → Underweight
2015-10-23 アップグレード JMP Securities Mkt Perform → Mkt Outperform
すべてを表示

Enanta Pharmaceuticals Inc (ENTA) 最新ニュース

pulisher
Sep 26, 2026

How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 26, 2026
pulisher
Sep 25, 2026

Enanta Pharmaceuticals stock falls 1.25 percent to USD 11.85 - AD HOC NEWS

Sep 25, 2026
pulisher
Sep 25, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 25, 2026
pulisher
Sep 23, 2026

ENTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada

Sep 23, 2026
pulisher
Sep 22, 2026

Enanta Pharmaceuticals stock trades at USD 12.11 - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 17, 2026

Enanta Pharmaceuticals reports new STAT6 inhibitors - BioWorld News

Sep 17, 2026
pulisher
Sep 16, 2026

Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily

Sep 16, 2026
pulisher
Sep 16, 2026

Enanta at H.C. Wainwright conference: RSV path sharpens By Investing.com - Investing.com Canada

Sep 16, 2026
pulisher
Sep 10, 2026

The One-Carbon Mistake That Cost A Patent Its Priority Date - marketscreener.com

Sep 10, 2026
pulisher
Sep 06, 2026

(ENTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 05, 2026

ENTA stock holds steady as Enanta Pharmaceuticals focuses on antiviral pipeline - AD HOC NEWS

Sep 05, 2026
pulisher
Sep 04, 2026

Enanta Pharmaceuticals stock gains after new SEC filing and solid cash position - AD HOC NEWS

Sep 04, 2026
pulisher
Sep 01, 2026

Enanta Pharmaceuticals to Participate in September Investor Conferences - finance.yahoo.com

Sep 01, 2026
pulisher
Sep 01, 2026

Enanta stock holds in the low teens as investors look to recent trial and earnings progress - ad-hoc-news.de

Sep 01, 2026
pulisher
Aug 23, 2026

Enanta (ENTA) Watch: Finishes 2.59% Up at $13.47 for the Current Session; Boundary Watch: the Price Remains Bounded by the Supplied Support and ResistanceMoney Flow Index - vinanet.vn

Aug 23, 2026
pulisher
Aug 20, 2026

Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S - GuruFocus

Aug 20, 2026
pulisher
Aug 14, 2026

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - Kalkine

Aug 14, 2026
pulisher
Aug 12, 2026

Enanta Pharmaceuticals Announces Q3 Fiscal 2026 Financial Results - Kalkine Media

Aug 12, 2026
pulisher
Aug 11, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 11, 2026
pulisher
Aug 10, 2026

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts

Aug 10, 2026
pulisher
Aug 10, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - tradingview.com

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - Barchart.com

Aug 10, 2026
pulisher
Aug 10, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire

Aug 10, 2026
pulisher
Aug 10, 2026

ENANTA PHARMACEUTICALS ($ENTA) Releases Q3 2026 Earnings - quiverquant.com

Aug 10, 2026
pulisher
Aug 07, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Aug 07, 2026
pulisher
Aug 07, 2026

Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Call Dominated - vinanet.vn

Aug 07, 2026
pulisher
Aug 06, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026
pulisher
Aug 03, 2026

Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026
pulisher
Jul 30, 2026

Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 30, 2026
pulisher
Jul 27, 2026

ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170 - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Enanta Pharmaceuticals Inc (ENTA) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com

Jul 27, 2026
pulisher
Jul 27, 2026

Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

ENTA|Enanta Pharmaceuticals Inc|Price:12.730|Chg%:-0.050 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Enanta Pharmaceuticals (ENTA) Slides to $12.78 as Selling Pressure PersistsPercent Below MA - dars.gov.et

Jul 25, 2026
pulisher
Jul 24, 2026

Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Enanta Pharmaceuticals (ENTA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 24, 2026
pulisher
Jul 24, 2026

Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

Enanta Pharmaceuticals (9EP) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 23, 2026
pulisher
Jul 23, 2026

Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra

Jul 23, 2026
pulisher
Jul 23, 2026

Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jul 23, 2026

Enanta Pharmaceuticals Inc (ENTA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):